Insights & Resources – COD Research – Designing Therapies For Future

The Evolution of PRO Collection: From Paper Diaries to ePRO Systems

Transforming Complexity into Success: A Large-Scale Global Phase III Biosimilar Dermatology Trial

Biometrics

Clinical Services

CT Quality Assurance

Medical Affairs

Pulmonary Disease Introduction: Prevalence, Causes, Prevention & Treatment

Strategic Planning for Patient Recruitment

EMA
FDA
MHRA

EMA risk management information day, European Medicines Agency, Amsterdam, the Netherlands, from 8 September 2026, 09:00 (CEST) to 8 September 2026, 17:00 (CEST)
Source: EMA Published on 2026-08-21
Human medicines European public assessment report (EPAR): Epivir, lamivudine, Date of authorisation: 08/08/1996, Revision: 51, Status: Authorised
Source: EMA Published on 2026-08-20
Timetable: Post-authorisation measures (PAMs) assessed by PRAC - ATMP
Source: EMA Published on 2026-08-20
Timetable: Post-authorisation measure (PAM) assessed by PRAC
Source: EMA Published on 2026-08-20
Guidance and template for industry on implementing Shortage Prevention Plans (SPP)
Source: EMA Published on 2026-08-20
Guidance and template for industry on implementing Shortage Prevention Plans (SPP)
Source: EMA Published on 2026-08-20

Read More